|  
  
    | 
      
     | 
   
   
     | 
   
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
   
  
    
      
	
	  
	     |  
	    
	      
	        
            
                | Çã°¡Á¤º¸ | 
                         
	         
	       | 
	     
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
        
        643900200[A05002601]  
	    
	    Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \0 ¿ø/1ݼ¿(2012.08.01)(ÇöÀç¾à°¡) 
            \117 ¿ø/1ݼ¿(2006.06.01)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      ¹é»ö³»Áö ¹ÌȲ»öÀÇ ¾×»ó ³»¿ë¹°ÀÌ µé¾î ÀÖ´Â Àû°¥»öÀÇ ¿¬Áúݼ¿  
      
	    [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    30ĸ½¶, 100ĸ½¶ | 
   
  
  
  
   
    | Æ÷À塤ÄÚµå´ÜÀ§ | 
    
        
        
            | ¾àǰ±Ô°Ý | 
            ´ÜÀ§ | 
            ´ëÇ¥ÄÚµå | 
            Ç¥ÁØÄÚµå | 
            ºñ°í | 
	     
        
        
            | 80¹Ð¸®±×·¥ | 
            100 ĸ½¶ | 
            8806439002002 | 
            8806439002026 | 
             | 
	     
        
        
            | 80¹Ð¸®±×·¥ | 
            30 ĸ½¶ | 
            8806439002002 | 
            8806439002019 | 
             | 
	     
        
         
     | 
   
      
  
  	
   
    | ÁÖ¼ººÐÄÚµå | 
    
      165602ACS  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
     | 
   
  
  
  
  
  	
   
    | ´ëÇ¥ÄÚµå | 
    8806439002002 | 
   
  
  
  
  
   
    | º¸°ü¹æ¹ý | 
    ¹ÐÆó¿ë±â, ½Ç¿Â(1-25¡É)º¸°ü, 24°³¿ù | 
   
  
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
      
        [Á¶È¸]
     | 
      
  
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      Àν¶¸° ºñÀÇÁ¸¼º ¼ºÀÎÇü ´ç´¢º´ (½Ä»ç¿ä¹ý¡¤¿îµ¿¿ä¹ýÀ¸·Î ÃæºÐÇÑ È¿°ú¸¦ ¾òÀ» ¼ö ¾ø´Â °æ¿ì¿¡ ÇÑÇÔ) 
[Drugbank ÀÇ ¼ººÐÁ¤º¸¿¶÷] [Gliclazide]
      
      
      
      
     | 
   
  
  
  
  
  
  
  
  
    
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
     [󹿾à¾î] 
      [ÁÖ¼ººÐÄÚµå:165602ACS ¿¡ µû¸¥ ½É»çÁöħ¿¶÷] 
1ÀÏ 40-80mgÀ¸·Î ½ÃÀÛÇϸç, 1ÀÏ 1-2ȸ Åõ¿©ÇÑ´Ù. ȯÀÚÀÇ »óÅ¿¡ µû¶ó ¿ë·®À» Á¶ÀýÇÑ´Ù. 1ÀÏ ÃÑ Åõ¿©·®Àº 240mgÀ» ÃʰúÇÏÁö ¸» °Í     
      	    
     | 
   
  
  
  
  
  
  
   
    | °æ°í | 
    
         ÁßÁõ ¶Ç´Â Áö¿¬¼º ÀúÇ÷´çÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ¿ë¹ý¿ë·®, »ç¿ë»óÀÇ ÁÖÀÇ»çÇ׿¡ ƯÈ÷ À¯ÀÇÇÒ °Í
     | 
   
  
  
  
  
   
    | ±Ý±â | 
    
      - ÁßÁõ ÄÉÅä½Ã½º, ´ç´¢º´¼º È¥¼ö ¶Ç´Â ÀüÈ¥¼ö, Àν¶¸°ÀÇÁ¸Çü ´ç´¢º´È¯ÀÚ
 - ÁßÁõ °£±âÁõ, ½Å±â´É Àå¾ÖȯÀÚ
 - ÁßÁõ°¨¿°Áõ, ¼ö¼úÀüÈÄ, ÁßÁõ¿Ü»óȯÀÚ
 - ¼³»ç, ±¸Åä µî À§ÀåÀå¾Ö ȯÀÚ
 - ÀÌ ¾à ¼ººÐ ¶Ç´Â ¼³Æù ¾Æ¹Ìµå°è¾àÁ¦¿¡ ´ëÇÏ¿© °ú¹ÎÁõÀÇ Àü·ÂÀÌ Àִ ȯÀÚ
 - ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ
    
 
  | 
   
  
  
  
  
   
    | ½ÅÁßÅõ¿© | 
    - °£±â´É, ½Å±â´ÉÀå¾ÖÀÇ Àü·ÂÀÌ Àִ ȯÀÚ
 - ´ÙÀ½°ú °°Àº ÀúÇ÷´çÀ» ÀÏÀ¸Å³ À§ÇèÀÌ Àִ ȯÀÚ ¶Ç´Â »óÅÂ
- °£ ¶Ç´Â ½Å±â´É Àå¾Ö
 - ³úÇϼöü ±â´É ºÎÀü ¶Ç´Â ºÎ½Å±â´É ºÎÀü
 - ¿µ¾çºÒ·® »óÅÂ, ±â¾Æ»óÅÂ, ºÒ±ÔÄ¢ÀûÀÎ ½Ä»ç¼·Ãë, ½Ä»ç ¼·Ãë·®ÀÇ ºÎÁ· ¶Ç´Â ¼è¾à »óÅÂ
 - °Ý·ÄÇÑ ±ÙÀ° ¿îµ¿
 - °úµµÀÇ ¾ËÄÚ¿Ã ¼·ÃëÀÚ
 - °í·ÉÀÚ
 - »óÈ£ÀÛ¿ëÀÇ 1)¿¡ Ç¥½ÃÇÑ ¾àÁ¦¿Í º´¿ë
 
  
  | 
   
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
      -  ÀúÇ÷´ç :
   Å»·Â°¨,  °íµµÀÇ °øº¹°¨, ¹ßÇÑ, ½É°èÇ×Áø, ÁøÀü, µÎÅë, Áö°¢ÀÌ»ó, ºÒ¾È, ÈïºÐ,  ½Å°æ°ú¹Î, ÁýÁß·ÂÀúÇÏ, Á¤½ÅÀå¾Ö, ÀǽÄÀå¾Ö, °æ·ÃµîÀÌ ³ªÅ¸³¯ ¼ö  ÀÖ´Ù. ¼¼È÷ ÁøÇàÇÏ´Â ÀúÇ÷´ç¿¡´Â ½Å°æÀå¾Ö, ÀǽÄÀå¾Ö µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÒ °Í
 Ç÷¾× : ¶§¶§·Î ºóÇ÷, ¹éÇ÷±¸ °¨¼Ò°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
°£Àå : ¶§¶§·Î °£±â´É Àå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
 ½ÅÀå : ¶§¶§·Î BUN, Ç÷û Å©·¹¾ÆÆ¼´ÑÀÇ »ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
 À§Àå : ¶§¶§·Î  ½Ä¿åºÎÁø, ±¸Åä, ±¸¿ª, µå¹°°Ô À§ÆØ¸¸°¨, º¹Åë, ¼³»ç, º¯ºñ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
 °ú¹ÎÁõ  : ¶§¶§·Î ÇǺμҾçÁõ, ¹ßÁø,  µå¹°°Ô ±¤¼±°ú¹ÎÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
 ±âŸ : ¶§¶§·Î µÎÁß, µÎÅë, Çö¿î, ¿°¨ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
          
     | 
   
  
  
    
   
    | ÀϹÝÀû ÁÖÀÇ | 
    - ´ç´¢º´À¸·Î È®½ÇÈ÷ Áø´ÜµÈ ȯÀÚ¿¡ ´ëÇØ¼¸¸ Àû¿ëÀ» °í·ÁÇÒ °Í. ´ç´¢º´ À̿ܿ¡µµ ³»´ç´ÉÀÌ»ó, ´¢´ç¾ç¼ºµî ´ç´¢º´ À¯»ç Áõ»ó(½Å¼º´ç´¢, ³ëÀμº ´ç´ë»ç ÀÌ»ó, °©»ó¼± ±â´É ÀÌ»ó µî)À» °¡Áø ÁúȯÀÌ ÀÖ´Â °æ¿ì¿¡´Â À¯ÀÇÇÒ °Í
 -  ÀÌ ¾à »ç¿ëÀº ¹Ì¸® ´ç´¢º´ Ä¡·áÀº ±âº»ÀÎ ½Ä»ç¿ä¹ý, ¿îµ¿¿ä¹ýÀ» ÃæºÐÈ÷ ÇàÇÑ ÈÄ¿¡ È¿°ú°¡ ºÒÃæºÐÇÑ °æ¿ì¿¡ ÇÑÇÏ¿© °í·ÁÇÒ °Í
 -  ÀÌ ¾àÀ»  Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â ¼Ò·®ºÎÅÍ ½ÃÀÛÇϰí Ç÷´ç, ´¢´çÀ» Á¤±âÀûÀ¸·Î °Ë»çÇÏ¿© ¾àÁ¦ÀÇ È¿°ú¸¦ È®ÀÎÇÏ¿© È¿°ú°¡ ºÒÃæºÐÇÑ °æ¿ì¿¡´Â ½Å¼ÓÈ÷ ´Ù¸¥ Ä¡·á¹ýÀ¸·Î ´ëüÇÒ °Í
 -  Åõ¿© °è¼Ó Áß¿¡, Åõ¿©ÀÇ Çʿ䰡 ¾ø´Â °æ¿ì¿Í °¨·®ÇÒ Çʿ䰡 ÀÖÀ»¼ö ÀÖ°í, ¶ÇÇÑ È¯ÀÚÀÇ  º´Á¶¸®¸¦ À߸øÇϰųª °¨¿°ÁõÀÇ ÇÕº´µî¿¡ ÀÇÇÏ¿© È¿°ú°¡ ³ªÅ¸³ªÁö ¾Ê°Å³ª ¶Ç´Â ºÒÃæºÐÇÑ °æ¿ì°¡ Àֱ⠶§¹®¿¡, ½Ä»ç¼·Ãë·®, üÁßÀÇ ÃßÀÌ, Ç÷´çÄ¡, °¨¿°ÁõÀÇ À¯¹« µî¿¡ À¯ÀÇÇÏ¸é¼ Ç×»ó Åõ¿© °è¼ÓÀÇ ¿©ºÎ, Åõ¿©·®, ¾àÁ¦ÀÇ ¼±Åà µî¿¡ ÁÖÀÇÇÒ °Í
 -  ÁßÁõ ¶Ç´Â  Áö¿¬¼º ÀúÇ÷´çÁõÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ³ôÀº  °÷¿¡¼ÀÇ ÀÛ¾÷ ÀÚµ¿Â÷ ¿îÀü µî¿¡ Á¾»çÇϴ ȯÀÚ¿¡ Åõ¿©ÇÏ´Â °æ¿ì¿¡´Â ÁÖÀÇÇÒ °Í. ¶ÇÇÑ ÀúÇ÷´çÁõ¿¡ ´ëÇÏ¿© ÁÖÀÇÇϰí ȯÀÚ ¹× ±× °¡Á·¿¡ ÃæºÐÈ÷ ÁÖÀǽÃų °Í
 -  ÀÌ ¾àÀº ¿øÄ¢ÀûÀ¸·Î ¾ËÆÄ-±Û·çÄڽôÙÁ¦ ÀúÇØÁ¦(¾ÆÄ«¸£º¸½º)¿ÍÀÇ º´¿ëÀº ÇÇÇÏ¸ç ºÎµæÀÌ º´¿ëÇÒ  °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. ¶ÇÇÑ, ÀÌ ¾àÀÇ Åõ¿©¿¡ ÀÇÇØ ÀúÇ÷´ç Áõ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â ÀϹÝÀûÀ¸·Î ¼´çÀ» Åõ¿©ÇÏ¸ç ¾ÆÄ«¸£º¸½º¿ÍÀÇ º´¿ë¿¡ ÀÇÇØ ÀúÇ÷´ç Áõ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Æ÷µµ´çÀ» Åõ¿©ÇÑ´Ù.
 
  | 
   
  
  
  
    
   
    | »óÈ£ÀÛ¿ë | 
     * ´ÙÀ½ ¾àÁ¦¿Í º´¿ë¿¡ ÀÇÇÏ¿©, Ç÷´ç°ÇÏ ÀÛ¿ëÀÌ Áõ° ¶Ç´Â °¨¾àÇÏ´Â °æ¿ì°¡ Àֱ⠶§¹®¿¡ À̰͵é°ú º´¿ëÇÏ´Â °æ¿ì¿¡´Â, Ç÷´çÄ¡, ȯÀÚÀÇ »óŸ¦ ÃæºÐÈ÷ °üÂûÇÏ¸é¼ Åõ¿©ÇÒ °Í.
- Áõ°ÇÏ´Â ¾àÁ¦
 
    Àν¶¸° Á¦Á¦, ºñ±¸¾Æ´Ïµå°è ¾àÁ¦, ¾ËÆÄ-±Û·çÄڽôÙÁ¦ ÀúÇØÁ¦(¾ÆÄ«¸£º¸½º), ÇǶóÁ¹·Ð°è ¼Ò¿°Á¦(Æä´ÒºÎŸÁ¸ µî), ÇÁ·Îº£³×½Ãµå, Äí¸¶¸°°è ¾àÁ¦, »ì¸®½Ç»êÁ¦(¾Æ½ºÇǸ°µî), º£Å¸Â÷´ÜÁ¦(ÇÁ·ÎÇÁ¶ó³ë·Ñ), MAOÀúÇØÁ¦, ¼³ÆÄÁ¦, µðÈ÷µå·Î¿¡¸£°íŸ¹Î Á¦Á¦, Ŭ·Î¶÷Æä´ÏÄÝ, Åׯ®¶ó»çÀÌŬ¸°°è Ç×»ý ¹°Áú, Ŭ·ÎÇǺ극ÀÌÆ®
 -  °¨¾àÇÏ´Â ¾àÁ¦
 
    ¿¡Çdz×ÇÁ¸°, ºÎ½ÅÇÇÁúÈ£¸£¸ó, °©»ó¼±È£¸£¸ó, ³Æ÷È£¸£¸ó, ÀÌ´¢Á¦, ÇǶóÁø¾Æ¹Ìµå, À̼ҴϾÆÁöµå, ´ÏÄÚÆ¾»ê, Æä³ëÄ¡¾ÆÁø°è ¾àÁ¦ 
  | 
   
  
  
  
   
    | ÀӺο¡ ´ëÇÑ Åõ¿© | 
    
      
	[ÀӺαݱ⠼ººÐ Á¶È¸]       
        ¼³Æ÷´Ò¿ì·¹¾Æ°è ¾àÁ¦´Â ŹÝÀ» Åë°úÇÑ´Ù´Â º¸°í°¡ ÀÖ°í ½Å»ý¾ÆÀÇ ÀúÇ÷´ç, ¶Ç´Â °Å´ë¾Æ°¡ È®Àεǰí ÀÖÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ ¿¡°Ô´Â Åõ¿©ÇÏÁö ¸» °Í.
     | 
   
  
  
  
  
  
  
  
   
    | ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© | 
    
      
       
       ¼Ò¾Æ¿¡ ´ëÇÑ ¾ÈÀü¼ºÀº È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù. | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  		
  
  
   
    | º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ | 
    ¹ÐÆó¿ë±â, ½Ç¿Â(1-25¡É)º¸°ü, 24°³¿ù | 
   
  	
  
  
    
   
    | ±âŸ | 
    - ¼³Æ÷´Ò¿ì·¹¾Æ°è ¾àÁ¦(ÅçºÎŸ¸¶À̵å 1ÀÏ 1.5g)À» Àå±â°£ °è¼Ó Åõ¿©ÇÑ °æ¿ì, ½Ä»ç¿ä¹ý ´Üµ¶ÀÇ °æ¿ì¿Í ºñ±³ÇÏ¿© ½ÉÀå, Ç÷°ü°è Àå¾Ö¿¡ ÀÇÇÑ »ç¸Á·üÀÌ À¯ÀÇÇÏ°Ô ³ô´Ù´Â º¸°í°¡ ÀÖ´Ù. 
 - Àν¶¸° ¶Ç´Â °æ±¸¿ë Ç÷´ç°ÇÏÁ¦ÀÇ Åõ¿© Áß¿¡ ¾ÈÁö¿ÀÅٽŠº¯È¯È¿¼Ò ÀúÇØÁ¦¸¦ Åõ¿©ÇÒ °æ¿ì, ÀúÇ÷´çÀÌ ³ªÅ¸³ª±â ½±´Ù´Â º¸°í°¡ ÀÖ´Ù.
 
  | 
   
  
  
  
  
  
      							
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¤º¸¿ä¾à | 
                 
	         
	       | 
	           	    
	     |  
	    | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ | 
                 
	         
	       | 
	           	    
	     |  
	    | 	 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | Á¦Ç°Á¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× | 
    
      
      
        
        643900200[A05002601]  
	    
	    Àú°¡¾à ´ëü Àμ¾Æ¼ºê Áö±Þ ´ë»ó
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸] 
          
        
        
        
          
          
            \0 ¿ø/1ݼ¿(2012.08.01)(Ãֽžడ)
            \117 ¿ø/1ݼ¿(2006.06.01)(º¯°æÀü¾à°¡)
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
    
     | 
   
  
  
   
    | Á¦Ç°¼º»ó | 
    
      ¹é»ö³»Áö ¹ÌȲ»öÀÇ ¾×»ó ³»¿ë¹°ÀÌ µé¾î ÀÖ´Â Àû°¥»öÀÇ ¿¬Áúݼ¿  
      
	  [Á¦ÇüÁ¤º¸ È®ÀÎ]
     |   
   
  
  
  
  
  
   
    | ´ëü°ü·Ã | 
    »ýµ¿¼º ½ÃÇè ¿Ï·á | 
                                    
  
  
  
  
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    30ĸ½¶, 100ĸ½¶ | 
   
  
  
  
   
    | º¸°ü¹æ¹ý | 
    ¹ÐÆó¿ë±â, ½Ç¿Â(1-25¡É)º¸°ü, 24°³¿ù | 
   
  
  
  
   
    µ¿ÀÏÁÖ¼ººÐÄÚµå  °Ë»ö¼øÀ§ | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
     | 
   
                                                          															
  
  
  
  
  
       
  
  
  
   
  |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | º¹¾àÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
  
   
    | Ãà¾àº¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Cµî±Þ 
				        
				         (ÀӽŠ±â°£ µ¿¾È Ç÷´ç ·¹º§À» À¯ÁöÇϱâ À§Çؼ´Â Àν¶¸°ÀÌ ÃßõµÊ. Ãâ»ê½Ã¿¡ sulfonylurea°¡ Åõ¿©µÉ °æ¿ì Àå±â°£ÀÇ ÁßÁõ ½Å»ý ÀúÇ÷´çÁõÀÌ ¹ß»ýÇÒ ¼ö ÀÖ´Ù. )
				        
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  
   
    ½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  
   
    | º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ | 
    
      [º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
     | 
   
  	
  
  
  
   
    | º¹¾à¶óº§ | 
    
    
    
      | À̹ÌÁö | 
      º¹¾à¼³¸í | 
     
    
    
        | 
      ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö | 
     
    
       | 
     
    
    
        | 
      º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. | 
     
    
       | 
     
    
     |  
    
      
	
	  
            | *  | 
	    º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. | 
	   
	  
            | *  | 
	    º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. | 
	   
	  
            | *  | 
	    ±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. | 
	   
	   
     |   
     | 
   
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
	   
	 
	
	  
       |  
	    
	      
	        
            
                | ½É»çÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	     |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | ÇмúÁ¤º¸ | 
                             
	         
	       | 
	           	  
	     |  
	    
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | Mechanism of Action | 
    
       Gliclazide¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Gliclazide binds to the beta cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the beta cells. This opens voltage-dependent calcium channels in the beta cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules. 
     | 
   
  
   
    | Pharmacology | 
     
       Gliclazide¿¡ ´ëÇÑ Pharmacology Á¤º¸ Gliclazide is a second generation sulphonylurea which acts as a hypoglycemic agent. It stimulates beta cells of the islet of Langerhans in the pancreas to release insulin. It also enhances peripheral insulin sensitivity. Overall it potentiates insulin release and improves insulin dynamics. 
     | 
   
  
   
    | Protein Binding | 
    
       Gliclazide¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available 
     | 
   
  
   
    | Half-life | 
    
       Gliclazide¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 11 hours (Campbell DB et al.,Diabetes Res Clin Pract.;14:S21-36) 
     | 
   
  
   
    | Absorption | 
    
       Gliclazide¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly and well absorbed but may have wide inter- and intra-individual variability. 
     | 
   
  
   
    | Pharmacokinetics | 
    
       GliclazideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
- Èí¼ö : ´ëºÎºÐÀÌ À§Àå°ü¿¡¼ Èí¼öµÈ´Ù.
 
 - Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : ¼ºÀÎ : 4 ½Ã°£
 
 - ºÐÆ÷ : ºÐÆ÷¿ëÀû : 25 L
 
 - ´Ü¹é°áÇÕ : 95% (85-97%)
 
 - ÀÛ¿ë Áö¼Ó ½Ã°£ : 10-20 ½Ã°£
 - ´ë»ç : 80% ÀÌ»óÀÌ °£´ë»çµÈ´Ù.
 
 - ¹Ý°¨±â : 10½Ã°£ (6-14 ½Ã°£)
 
 - ¼Ò½Ç : 20% ¹Ì¸¸ÀÌ ¹Ìº¯Èü·Î 95%°¡ ½ÅÀåÀ» ÅëÇØ ¹è¼³µÈ´Ù.
    
	 
	 
	
     | 
   
  
   
    | Biotransformation | 
    
       Gliclazide¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic 
     | 
   
  
   
    | Toxicity | 
    
       Gliclazide¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=3000 mg/kg (orally in mice) 
     | 
   
  
   
    | Drug Interactions | 
    
       Gliclazide¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Acebutolol	The beta-blocker decreases the symptoms of hypoglycemiaAtenolol	The beta-blocker decreases the symptoms of hypoglycemiaBetaxolol	The beta-blocker decreases the symptoms of hypoglycemiaBevantolol	The beta-blocker decreases the symptoms of hypoglycemiaBisoprolol	The beta-blocker decreases the symptoms of hypoglycemiaCarteolol	The beta-blocker decreases the symptoms of hypoglycemiaCarvedilol	The beta-blocker decreases the symptoms of hypoglycemiaEsmolol	The beta-blocker decreases the symptoms of hypoglycemiaLabetalol	The beta-blocker decreases the symptoms of hypoglycemiaMetoprolol	The beta-blocker decreases the symptoms of hypoglycemiaNadolol	The beta-blocker decreases the symptoms of hypoglycemiaOxprenolol	The beta-blocker decreases the symptoms of hypoglycemiaPenbutolol	The beta-blocker decreases the symptoms of hypoglycemiaPindolol	The beta-blocker decreases the symptoms of hypoglycemiaPractolol	The beta-blocker decreases the symptoms of hypoglycemiaPropranolol	The beta-blocker decreases the symptoms of hypoglycemiaSotalol	The beta-blocker decreases the symptoms of hypoglycemiaTimolol	The beta-blocker decreases the symptoms of hypoglycemiaAspirin	The salicylate increases the effect of sulfonylureaBismuth Subsalicylate	The salicylate increases the effect of sulfonylureaSalicylate-magnesium	The salicylate increases the effect of sulfonylureaSalicylate-sodium	The salicylate increases the effect of sulfonylureaSalsalate	The salicylate increases the effect of sulfonylureaTrisalicylate-choline	The salicylate increases the effect of sulfonylureaRepaglinide	Similar mode of action - questionable associationRifampin	Rifampin decreases the effect of sulfonylureaTranylcypromine	The MAO inhibitor increases the effect of the hypoglycemic agentPhenelzine	The MAO inhibitor increases the effect of the hypoglycemic agentIsocarboxazid	The MAO inhibitor increases the effect of the hypoglycemic agentPhenylbutazone	Phenylbutazone increases the effect of the hypoglycemic agentGlucosamine	Possible hyperglycemiaDicumarol	The agent increases the effect of sulfonylureaChloramphenicol	The agent increases the effect of sulfonylureaClofibrate	The agent increases the effect of sulfonylurea 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] 
     | 
   
  
   
    | Food Interaction | 
    
       Gliclazide¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.Avoid alcohol. 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Gliclazide¿¡ ´ëÇÑ Description Á¤º¸ An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion. [PubChem] 
     | 
   
  
   
    | Dosage Form | 
    
       Gliclazide¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Tablet	OralTablet, extended release	Oral 
     | 
   
  
   
    | Drug Category | 
    
       Gliclazide¿¡ ´ëÇÑ Drug_Category Á¤º¸ Hypoglycemic AgentsSulfonylureas 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Gliclazide¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Gliclazide¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1C[C@@H]2CCC[C@@H]2C1 
     | 
   
  
   
    | InChI Identifier | 
    
       Gliclazide¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)/f/h16-17H 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Gliclazide¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea 
     | 
   
    
  |  
	   
	   
	
	  
       |  
	    
	      
	        
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ | 
                             
	         
	       | 
	           	  
       |  
	     |  
	   
	     	
 
  | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
              
 
              - 
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
                    
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
  [ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â]       Á¦¸ñ ¾øÀ½ 
 
    
    2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
    
    1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ  º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
    ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
          
    
    
    
    2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
    ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
 
 
 
   
  |